26.08.2010
- Sanofi-Aventis shareholders L'oreal and Total worry that the French drugmaker will pay too much for U.S. biotech company Genzyme and are not convinced it is the best fit, bankers...
26.08.2010
- Sanofi-Aventis is not willing to pay more than $70 per share for U.S. biotech Genzyme and may look at alternative targets, Bloomberg reported on Wednesday, citing sources familiar...
05.07.2010
- Sanofi-Aventis declined to comment on Friday on a Bloomberg report that it was preparing an acquisition of $20 billion or more in the U.S. as shares in the French drugmaker fell...
